LENZ Therapeutics, Inc.
NMS: LENZLive Quote
📈 ZcoreAI Score
Our AI model analyzes LENZ Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get LENZ Z-Score →About LENZ Therapeutics, Inc.
Healthcare
Biotechnology
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
📊 Fundamental Analysis
LENZ Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -33.6%, which indicates that capital utilization is currently under pressure.
At a current price of $9.07, LENZ currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $8.25 - $50.40).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$284.38M
Trailing P/E
--
Forward P/E
-3.44
Beta (5Y)
2.29
52W High
$50.40
52W Low
$8.25
Avg Volume
1.05M
Day High
Day Low